Subject Index
A
Abdominal pain
_celiac plexus block for, 411
_in children, 221
Abstinence scores, 335
Abstinence syndrome, 333-335,337
Aching pain, 68,77
Acquired immunodeficiency syndrome
(AIDS) patients
_dementia of, 55,58
_functional impairment, 270
_pain syndromes, 58-59
_suicidal ideation by, 55,56-57
Acupuncture, as neuropathic pain therapy,
364
Acyclovir, 254
Addiction, 332
_medical examining boards' definition,
327
_patients' concerns about, 325-326,399-400
_tolerance in, 333-335. See also
Tolerance
Addiction Research Center, 335
Adenosine, in inflammatory hyperalgesia,
24
Adenosine-3;pr,5;pr-cyclic monophosphate
(cAMP), in inflammatory
hyperalgesia, 24,25
Adjustment disorders
_of leukemia patients, 3
_as suicide risk factor, 51,53
Adolescent patients, behavioral
interventions for, 417
Adolescent Pediatric Pain Tool, 228,229,
230
Adrenal gland, depression-related
hypertrophy, 9-10
Adrenergic receptors, in sympathetically
maintained pain, 108
Adrenocorticotropic hormone (ACTH), as
depression marker, 9
Adriamycin, as mucositis cause, 252
Affect. See Emotion
Afferent fibers, primary
_calcitonin gene-related peptide content,
69,70,78
_of cutaneous nerves, 68
_dorsal, opioid receptor binding sites,
135-139
_hyperalgesia and, 23-24
_of joints, 68,69,103
_of muscle, 68,69
_silent, 103,104
_visceral, 101,102-104,109
Ab fibers, in neuropathic pain,
129-130
A[bj3]e fibers. See also Ae mechanical
nociceptors
_in burning pain, 68
_dorsal horn termination site, 69
_in pricking pain, 68,77
_as tissue injury transducers, 89
Agency for Health Care Policy and
Research, cancer pain management
guidelines, 329
Air Force personnel, HIV-infected, suicide
by, 55
Alcoholism, as suicide risk factor, 56
Alfentanil
_infusion termination, 189
_as pediatric sedative, 378
_pharmacodynamic effects, 185
Alkylating agents, nucleic acid damage by,
252
Allodynia, 105,107-108
_in experimental mononeuropathy,[ql
141-147
Alprazolam, as neuropathic pain therapy,
362
Ae mechanical nociceptors, 67
_in primary hyperalgesia, 69
Ae mechanoheat nociceptors, 67
American Medical Association, cancer
pain management guidelines, 329
American Pain Society, 386
_cancer pain management guidelines,[ql
329
d-Aminobutyric acid (GABA), in
tolerance, 37
[ecAmitriptyline, analgesic effects, 358
Amputation-related pain. See also
Phantom limb pain
_in children, 221
Amygdala
_anatomy, 86,87
_emotional arousal role, 88
Analgesia. See also Opiate(s); Opioid(s);
Opioid receptor agonists
_adjuvant, as neuropathic pain therapy,
356,357-363
_genetic determinants, 37-40
_stimulation-produced, 31-32
Anesthesia
_general, for children, 378
_local. See Local anesthesia
Angina, cutaneous hyperalgesia of, 99
Anhedonia, as depression symptom, 1,2
Anoxia, as visceral pain cause, 102
Antibiotic therapy
_antimitotic effects, 252
_as neuropathic pain therapy, 355
Anticonvulsants
_antidepressant therapy failure and, 412
_as neuropathic pain therapy, 359-360
Antidepressants, 412
_efficacy, 13-14,15-16
_as minor depression therapy, 3
_as morphine tolerance antagonists, 119
_serotonergic neurotransmission effects,
12
_tricyclic
__dosage, 358-359
__as neuropathic pain therapy, 356,[ql
357-359
Antimetabolites, nucleic acid damage by,
252
Antisocial behavior, individual variability
in, 301
Anxiety, cancer pain-related
_in children, 222
_pain severity relationship, 269
Anxiety inventories, 208
Anxiolytics, for procedure-phobic patients,
398-399
Appetite loss, depression-related, 1-2
Arachidonic acid, nonsteroidal
antiinflammatory drug-related
inhibition, 23
Arginine vasopressin, in tolerance, 37
Aristotle, 83
Arousal, emotional, 92-93,205
Arthritis
_acute experimental, 72,73,75,78
_HIV infection-related, 59
Asparaginase, stomatotoxicity, 252
[cf2]=+Aspergillus[cf1] infection, oral, 254
Aspirin, as arachidonic acid metabolism
inhibitor, 23
Auditory stimuli, emotional responses, 88
Autonomic dysregulation, in neuropathic
pain, 353
Autonomy, of patients, 388-390
2>B2>
Baclofen, as neuropathic pain therapy, 359
Bacterial infections, cancer therapy-
related, 253,254-255
Barriers Questionnaire, 326-327
Beck Depression Inventory, 208,214
Behavioral interventions, for cancer pain
management. See also Cognitive-
behavioral interventions;
Distraction; Guided imagery;
Hypnosis; Relaxation techniques
_elderly patients' resistance to, 416-417
_group discussion on, 415-418
_immediacy of outcome, 415
_limited use of, 328
_for oral mucositis pain management, 255
Behavioral observation methods, for
pediatric pain assessment, 233-238
Behavioral Observation Tool, 236
[bcBehavior Rating Scales, of pain intensity,
200-201,204
Beneficence, 388,390
Benzodiazepines
_as neuropathic pain therapy, 362
_for pediatric sedation, 373,377
Beta-adrenergic blockers, 94-95
Bleomycin, as mucositis cause, 252
Blood drawing. See Venipuncture
Body maps, for pain self-reporting,[ql
228-229,230
Bone, radiation-related damage, 251
Bone marrow aspiration, in children,
221,372,373,374,375
_preparation for, 381-382
_sedation for, 377
Bone marrow suppression, chemotherapy-
related, 248,252-253
Bone marrow transplant patients
_Aspergillus infections, 254
_depression in, 3
_oral hemorrhage, 255
_oral mucositis, 190,248
__rating scale, 258,260-262
_patient-controlled analgesia, 190
Bone pain, colony-stimulating factor-
related, 59
Box Scale, 201-202,204
BPI Pain Assessment battery, 212
Bradykinin
_as inflammatory pain mediator, 22-23,25
_nociceptor sensitizing effect, 69
Brain. See also specific areas of brain
_depression-related structural
abnormalities, 13
_morphine-sensitive areas, 120
Breast cancer patients
_depression in, 4,15
_suicide risk, 50,53
_support groups, 404-405
_symptom reporting by, 159
Breast self-examination, 159-160
BUBU. See Enkephalins, [D-Ser2(O-tert-butyl),Leu5,Thr6(O-tert-butyl)]
Buddha, 83
Buproprion, 14
Burning pain, 68,77
_of causalgia, 143
BW 373U86, 182
2>C2>
C5a, 23
Calcitonin gene-related peptide, afferent content, 69,70,78
Calcium, in G protein-opioid receptor decoupling, 37
Cancer pain
_debilitating, 53
_individual variability of, 195
_inflammatory hyperalgesic mediators, 21-29
__altered pain sensation and, 22
__bradykinin, 22-23
__leukotriene B;i4, 23
__prostaglandins, 23-24
__second messengers, 24
__therapeutic implications, 24-25
_onset, 321
_patients' beliefs about, 325-327,399-400
_patients' denial of, 94
_patients' fear of, 21
_prevalence, 53,322
_public attitudes toward, 53-54
_sources, 195
Cancer pain management
_barriers to, 321-328
__documentation of, 321-322
__health care professionals-related,322-324
__health care system-related, 327-328
__patient education implications, 399-401
__patient-related, 325-327
__reduction of, 328-329
_guidelines, 329
_inadequate, 193,323,386,399
_legal aspects, 329
_as physicians' duty, 386
_physicians' lack of training in, 323
Cancer therapy. See also Chemotherapy;
Radiation therapy
_oral complications, 247-265
Candidiasis, oral, 253-254,263
Capsaicin, 23
_as neuropathic pain therapy, 361-362
_spinothalamic tract cellular response, 72,73,74,76
Carbamazepine
_leukopenic effect of, 360
_as neuropathic pain therapy, 359,360
Cardiovascular disease, hostility-related, 165
Care ethics, 386,391
Carisoprodol, 363
Cartoon-face pain scales, 225,227-228
Causalgia, experimental model, 143
Causal inference, 304-305
Celiac plexus block, 328,411
Center for Epidemiological Studies
Depression Scale, 208
Central nervous system
_depression-related abnormalities, 13
_as neuropathic pain site, 351,352,353-354
_pain-inhibitory function, 31,115
Central pain, 353
Central sensitization
_excitatory amino acids in, 76
_N-methyl-[smd[nm-aspartate receptor-mediated, 35
_in visceral hyperalgesia, 104-105,107-108
Cerebellum, in mood disorders, 13
Cerebrospinal fluid, in depression, 9
C fibers
_in burning pain, 68
_in primary hyperalgesia, 69
_as tissue injury transducers, 89
Chemotherapy
_as cancer pain cause, 195
__in children, 221,372
_guided imagery intervention for, 415
_as mucositis cause, 247-248,252-253
_as neuropathic pain cause, 352
_as neuropathic pain therapy, 355
Chemotherapy patients, symptom
reporting by, 159
Childhood cancer-related pain
_assessment, 219-246,406
__behavioral observation methods,233-239
__pain experience factors, 220-222
__pain history, 223-225
__pain measurement tool selection,239-240
__physiological approaches, 238-239
__proxy measures of pain, 231-233
__self-reports, 225-231,273
__unstructured observations, 240-241
_concurrent symptoms, 222
_family factors affecting, 221-222
_incidence, 220
_invasive procedure-related, 220
_management, 371-383
__algorithms for specific procedures, 381-382
__epidemiology, 372
__behavioral interventions, 417
__individual pain responses and, 373-375
__of procedure-related pain, 372,373
__psychological interventions, 405-406
__treatment approaches, 375-381
_phobic behavior patterns, 88
_therapy-related, 220,221
Children
_antisocial behavior, 301
_cancer pain in. See Childhood cancer-related pain
Children's Hospital Eastern Ontario Pain Scale, 235
Chloral hydrate, for pediatric sedation, 373,376
Chlorpromazine, as neuropathic pain therapy, 362
Chlorprothixene, as neuropathic pain therapy, 362
Chlorzoxazone, as musculoskeletal pain therapy, 363
Cholecystokinin, somatostatin-related inhibition, 11
Cholecystokinin antagonists, opiate tolerance effects, 37,119
Chronic pain, behavioral interventions for, 416
Cingulate gyrus
_anatomy, 87
_in negative emotions, 88
Cis-platin, as mucositis cause, 252
Clinical Scoring System for Measurement of Postoperative Pain, 234
Clinical trials
_of cancer pain management strategies, 329
_design, 283-299
__choice of controls, 285-290
__choice of treatments, 285-290
__chronic dosing studies, 288-290
__dose-ranging studies, 290
__drug combinations studies, 292
__equivalency of treatments studies, 291-292
__explanatory/pragmatic schema of, 284-285
__outcome measures, 296-297,303-304
__parallel versus crossover designs,292-294
__patient sample selection, 294-296
__positive controls, 285-290
__relative potency studies, 290-291
__side effects assessment, 296-297
_of psychological interventions, 404-405
_symptom reporting in, 159-160
Clomipramine, analgesic effects, 358
Clonazepam, as neuropathic pain therapy, 359,362
Clonidine, as neuropathic pain therapy, 361
C mechanoheat receptor, 67
Cognition, as psychological intervention target, 396
Cognitive-behavioral interventions, 396-397,405,406,407
Cognitive interventions
_for chronic pain management, 416
_for oral mucositis pain management, 255
Colon cancer patients, depression in, 4,7
Colony-stimulating factor, as bone pain cause, 59
Color pain scales, 228
Common cold
_depression and, 166
_self-care procedures, 156
Communication
_emotional, 85-86
_with family of cancer patients, 396
_patient-physician
__information component, 397-399
__pain management implications, 325
__patients' attitudes toward, 400
Compliance, 326,400
Computed tomography (CT), of children, 375,381
Concentration-effect curve, 185-187,190
Conditioning, classical, in pain, 86, 87-88
Confusional disorders
_cancer pain medication-related, 325-326
_depression-related, 1-2
_as suicide risk factor, 51
Connective tissue, radiation-related injury, 251
Constipation, opioid receptor-mediated, 122,123
Consultation, regarding suicidal patients, 62,63
Control, loss of, as suicide risk factor, 51-52
Coping strategies
_for cancer pain management, 401-406
_definition, 397
_outcome appraisal following, 156,157
_stress and, 166-167
Cordotomy, 411-412
_as neuropathic pain therapy, 365
Coronary events, emotion-induced, 166
Corticosteroids
_as neuropathic pain therapy, 361
_stomatotoxicity, 252
Corticotropin-releasing factor, as depression marker, 9,10
Cortisol
_as depression marker, 9
_limbic neuronal response, 93
CP96,345, 76
C polymodal nociceptor, 67
_in burning pain, 77
Cronbach's alpha, 274-275
Cross-modality matching, 198
Crossover design, 297
_parallel design versus, 292-294
Cross-tolerance
_definition, 331
_incomplete, 340,341,345
_to mixed agonist/antagonist drugs,336,338,339,340
_receptor mechanisms, 118-119
Crying
_as pain expression, 233,237
_separation-related, 95
Culture of Pain, The (Morris), 386,390-391
Cyclobenzaprine, 363
Cytomegalovirus infection, oral, 254
[bc2>D2>
DADLE. See Enkephalins, ;obD-Ala;s2,[ql
D-Leu;s5,Cys;s6;cb
DAMGO
_antinociceptive effect, 144,146
_dorsal horn opioid binding sites, 134
__postrhizotomy, 136,137,138
[ecDarwin, Charles, 85
DDC, as peripheral neuropathy cause,[ql
58-59
DDI, as peripheral neuropathy cause,[ql
58-59
Deafferentation pain
_morphine effects, 134,135,147
_pathophysiology, 353-354
``Debbie'' (euthanasia case), 60
Decision-making
_ethical, 391
_patients' participation in, 386
Deep brain stimulation, as neuropathic
pain therapy, 364
Deep breathing, as coping strategy,[ql
403-404
Defensive behavior, 93-94
Delirium
_AIDS-related, 55,58
_of clinical trial participants, 296
_as suicide risk factor, 51,53,55
Deltorphins, 176,178
_cross-tolerance to, 179
Dem compound, 373
Dementia
_AIDS-related, 55,58
_of clinical trial participants, 296
_as suicide risk factor, 55
Demerol-Phenergan-Thorazine cocktail,
373
Denial, of cancer pain, 94
Dental treatment, prechemotherapy,[ql
254-255
Deoxyribonucleic acid (DNA) damage
_chemotherapy-related, 252
_radiation-related, 250
Dependence
_physical
__definition, 332
__human studies, 333-340
__mechanisms, 347-348
__tolerance relationship, 333-340
_psychological
__animal studies, 332-333
__definition, 332
Dependency
_as euthanasia motivation, 60
_pain severity relationship, 271-272
Depression
_in cancer patients, 1-19
__biological markers, 1,7-13
__cancer pain severity relationship, 269
__diagnosis, 1-3,7-13
__prevalence, 1,3-7,15
__psychiatric consultation studies of, 7,8
__as suicide risk factor, 51,53,54
__treatment, 13-15
_common colds and, 166
_in diabetics, 160
_genetic factors, 13
_in HIV-infected patients, 59
_interleukin-1 in, 169
_as suicide risk factor, 1-2
__in AIDS patients, 55,56
_symptom reporting effects, 163,166,169
_treatment, 13-15
Depression scales, 208
Dermatitis, radiation-related, 221,372
Descriptor Differential Scales
_of pain affect, 207,209
_of pain intensity, 202-203,205
Desensitization
_childhood cancer pain patients' use of,
380,381-382
_procedure-phobic patients' use of,[ql
398-399
Desipramine, analgesic effects, 358
Dexamethasone, as neuropathic pain
therapy, 361,412
Dexamethasone suppression test, of
depressed cancer patients, 10,11-12
Diabetics, symptom reporting by, 160
[cf2]=+Diagnostic and Statistical Manual-III-
Revised[cf1] (DSM-III-R), major
depression diagnostic criteria, 1-2
Diagnostic procedure-related pain, in
children, 372,373-382
Diaphoresis, as pediatric pain indicator,
238-239
Diazepam, as neuropathic pain therapy,
362
Dideoxycytidine (DDC), 58-59
Dideoxyinosine (DDI), 58-59
8(R),15-(S)-diHETE, 23,24
Dilantin, as peripheral neuropathy cause,
58-59
Disability, definition, 269
Distraction, 403,415
_children's use of, 380,406
Dorsal column stimulation, as neuropathic
pain therapy, 364
Dorsal horn
_in neuropathic pain, 353
_nociception inhibition in, 70
_nociceptive signal processing in, 69-71
_opioid receptor binding sites, 130-149
__afferent fiber distribution relationship,
135-139
__in experimental mononeuropathy,[ql
139-147
__postsynaptic proportions, 131,132,[ql
135
__postrhizotomy plasticity, 137-139,[ql
147-148
__presynaptic proportions, 131,132-135
__rostrocaudal axis distribution,[ql
130-132
_as visceral afferent termination site, 102
Dorsal horn neurons, viscerally stimulated,
102,103-104
Dorsal noradrenergic bundle, 90-92
Dorsal root entry zone lesion, as
neuropathic pain therapy, 365
Dose-ranging studies, 290
Dose-response curve, 290,291
Downregulation, of opioid receptors, 347
Doxepin, analgesic effects, 358
[bcDPDPE. See Enkephalins, ;obD-Pen;s2,[ql
D-Pen;s5;cb
Drug abusers, cancer pain management in,
327
Drug combinations studies, 292
Dynorphins, 115
Dysesthesia, lancinating
_anticonvulsant therapy, 359-360
_neuroleptic therapy, 362
[ecDysphoria, as depression symptom, 1,2
2>E2>
Eastern Cooperative Oncology Group,
322-323,324,325
Ebers papyrus, 83
Education, for cancer pain management
_of health care professionals, 323,329
_of patients, 329,399-401
_of pediatric patients, 405-406
Effect compartment models, 187-188
Effect size, 302-304,313-314
Eland Color Tool, 228,231
Elderly patients
_behavioral interventions for, 416-417
_pain assessment in, 273
Electroconvulsive shock therapy, 10,14
Electroencephalography (EEG), all-night
recording methods, 12-13
Emotion, 83-98
_adaptive functions, 85-89
_basic, 84
_cognition and, 88-89
_definition, 84-85
_as disease risk factor, 165-166
_illness cognition relationship, 163-169
_pain relationship, model of, 89-95
__central noradrenergic processing in,
89-90,94-95
__dorsal noradrenergic bundle in, 90-92
__hypothalamic-pituitary-adrenocortical
axis in, 92-94,95
__locus coeruleus in, 90-92,94
__nociception in, 89-90
__pain control implications, 94-95
__ventral noradrenergic bundle in, 92-93
_as psychological intervention target, 396
_social function, 85-86
Endogenous analgesia system, 70
Endorphin(s), as pediatric pain indicators,
238-239
[bcb-Endorphin, 115
_in ischemic pain, 169
_tolerance to, 341
Enkephalins, 115
_;obD-Ala;s2,D-Leu;s5;cb (DADLE), 176,[ql
179-180,341
_;obD-Ala;s2,Leu;s5,Cys;s6;cb (DALCE),
178,179,180
_;obD-Pen;s2,D-Pen;s5;cb (DPDPE), 176-177
__binding inhibition, 179
[ec__opioid receptor binding sites, 114,120
_;obD-Ser;s2,Leu;s5,D-Thr;s6;cb (DSLET),
176,177,179,180
_;obD-Ser;s2(O-[cf2]=+tert[cf1]-butyl),Leu;s5,Thr;s6(O-[cf2]=+tert[cf1]-
butyl);cb (BUBU), 177
__antinociceptive effect, 144,146,147
__central bioavailability, 181-182
_;obD-Thr;s2,Leu;s2,D-Thr;s6;cb (DTLET), 176,177
_leu, 175
Epidural block, with local anesthetics,[ql
412
Epidural opioid infusion
_cannulation for, 413
_with local anesthetics, 413
_of morphine, 131-132
_as neuropathic pain therapy, 364
Epidural steroid therapy, 412
Epinephrine, adrenal medulla release of,
93
Ergoreceptor, 68
Erythema
_chemotherapy-related, 253
_radiation-related injury, 251
Esophageal cancer patients, depression in,
7
Estrogen
_stomatotoxicity, 252
_in stress-induced analgesia, 35
Ethics, of cancer pain treatment, 385-391
European Organization for Research and
Treatment of Cancer, Quality-of-
Life assessment scale, 270-271
Eutectic mixture, of local anesthetics,
376,381
Euthanasia. See also Suicide
_active, 60
_illegality, 60,61
_legalization, 49
_motivations for, 60
_palliative care and, 61-62
_passive, 60
_patients' requests for, 54,59,60-61
Excitatory amino acids
_analgesic applications of, 35
_in central sensitization, 76
_in endogenous pain inhibition, 33
_somatic afferent fiber content, 69
Experimental design. See also Clinical
trials, design
_individual variability analysis in,[ql
301-319
__effect size, 302-304,313-314
__generic approach, 305-317
__graphical analysis, 306-317,318
__population sampling model, 304-305
2>F2>
Facial Action Coding System, 228
Facial expression scales, for pain intensity
assessment, 201
_cartoon-face scales, 225,227-228
_Oucher scale, 227,231
Family, of cancer pain patients,
communication with medical staff,
396
Family factors, in childhood cancer pain,
221-222
Fatigue
_depression and, 1-2
_as suicide risk factor, 52
Fear
_of cancer pain, 399
_locus coeruleus activation-related, 90
Fear conditioning, 87-88
Fentanyl
_age-related dosages, 189
_as pediatric sedative, 377
_pharmacodynamic effects, 185
Fight-or-flight response, 92
_pain inhibition during, 31-32
[cf2]=+Final Exit[cf1] (Humphry), 49
Flumazenil, as pediatric sedative, 377
5-Fluorouracil, as mucositis cause, 252
Fluoxetine, 14
Fluphenazine, as neuropathic pain therapy,
362
Formylmethionyleucylphenylalanine, 23
Forskolin, in inflammatory hyperalgesia,
24
[bcFrontal lobe, evolutionary development, 89
b-Funaltrexamine, 113,114,177-178,179
Functional capability. See also Quality-of-
life
_proxy reports of, 272-273
Fungal infections, cancer therapy-related, 253-254
2>G2>
Ganciclovir, 254
Gastrointestinal cancer patients, suicide
risk, 50
Gastrointestinal tract, distention-related
pain, 101
Gate control theory, of pain, 70,378-379
Genetic factors, in analgesia requirements, 121-122
Glycogen, somatostatin-related inhibition, 11
G proteins
_in inflammatory hyperalgesia, 24,25
_opioid receptor decoupling, 37
_in tolerance development, 346-348
Gram-negative bacterial infections, oral, 254
Granulocytopenia, 252
Graphic pain rating scales. See also Facial expression scales; Numerical Rating Scales
_for children, 225
_of pain intensity, 199
Grief, 86
Group therapy, for depression, 15
Guanethidine, as neuropathic pain therapy, 363
Guided imagery, 404,405
_as chemotherapy-pain intervention, 415
_children's use of, 380
_as depression therapy, 15
Gustave-Roussy Child Pain Scale, 235
Gynecological cancer patients, depression in, 10,14
2>H2>
Haloperidol, as neuropathic pain therapy, 362
Handicap, definition, 269
Headache, lumbar puncture-related, 221
Head and neck cancer patients
_depression in, 6,715
_oral infections, 253
_oral mucositis, 248,251
Health, World Health Organization definition, 269
Health care professionals. See alsoPhysicians
_cancer pain management role, 322-324
Health care system, cancer pain
management barriers of, 327-328
Helplessness, cancer pain-related, 396-397
Hemlock Society, 60
Hemorrhage, oral, 248,253,255,263
Herpes simplex infection, oral, 254
Hippocampus, in negative emotion, 88
Histamine, nociceptor sensitizing effect, 69
Hodgkin's disease patients, depression in, 5
Homosexuals, suicide risk, 57
Hopelessness, cancer pain-related,[ql
396-397
_as suicide risk factor, 51,54,55,397
Hormones. See also specific hormones
_as pediatric pain indicators, 238-239
Hostility, as cardiovascular disease risk
factor, 165
Humane and Dignified Death Act, 60
Human immunodeficiency virus (HIV) infection. See also Acquired immunodeficiency syndrome (AIDS) patients
_as suicide motivation, 57
5-Hydroxyindoleacetic acid, as depression marker, 12
Hyperalgesia
_inflammatory mediators, 21-29
_models, 76-77,78
__experimental mononeuropathy, 141-143
_neutrophil-dependent, 23
_primary, 23-